Related Experiment Video
Updated: Jun 18, 2026
Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
Published on: August 8, 2012
Selective death of human breast cancer cells by lytic immunoliposomes: Correlation with their HER2 expression level
Enrique Barrajón-Catalán1, María P Menéndez-Gutiérrez, Alberto Falco
1Molecular and Cellular Biology Institute, Miguel Hernández University, Alicante, Spain.
Abstract:
Trastuzumab (Herceptin) targets the human epidermal growth factor receptor 2 (HER2), which is overexpressed in 20-30% of breast and ovarian cancers carrying a bad prognosis. Our purpose was to target HER2-overexpressing human breast cancer cells with pegylated immunoliposomes bearing trastuzumab and containing melittin, which has recently shown anticancer properties. Using a panel of human breast cancer cells with different HER2 expression levels, these immunoliposomes decreased cancer cells viability in a dose-response manner and in correlation to their level of HER2 expression. Specific binding of the immunoliposomes to SKBr3 breast cancer cells was shown by ImageStream-based analysis. The morphological changes observed in the treated cells suggested a cytolytic process. This preclinical approach may suppose an effective strategy for the treatment of HER2-overexpressing tumors, and can support the development of an early phases I-II clinical trial. Trastuzumab resistant breast cancer cells (JIMT-1), can also be targeted using this approach.
Insights
New immunoliposomes loaded with melittin and trastuzumab effectively target HER2-overexpressing breast cancer cells. This preclinical strategy shows promise for treating HER2-positive tumors, including resistant cell lines.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Human epidermal growth factor receptor 2 (HER2) is overexpressed in 20-30% of breast and ovarian cancers, correlating with poor prognosis.
- Trastuzumab (Herceptin) is a targeted therapy for HER2-overexpressing cancers.
- Melittin exhibits anticancer properties.
Purpose of the Study:
- To develop and evaluate pegylated immunoliposomes carrying trastuzumab and melittin for targeting HER2-overexpressing cancer cells.
- To assess the efficacy of these immunoliposomes against breast cancer cells with varying HER2 expression levels.
Main Methods:
- Utilized a panel of human breast cancer cell lines with differential HER2 expression.
- Administered pegylated immunoliposomes containing trastuzumab and melittin.
- Assessed cancer cell viability through dose-response studies.
- Confirmed specific binding using ImageStream-based analysis.
- Evaluated morphological changes indicative of cytolysis.
Main Results:
- Immunoliposomes demonstrated a dose-dependent decrease in cancer cell viability, correlated with HER2 expression levels.
- Specific binding of immunoliposomes to HER2-overexpressing SKBr3 cells was confirmed.
- Observed morphological changes suggested a cytolytic mechanism of action.
- The approach successfully targeted trastuzumab-resistant breast cancer cells (JIMT-1).
Conclusions:
- Pegylated immunoliposomes carrying trastuzumab and melittin represent a promising preclinical strategy for HER2-overexpressing tumors.
- This approach shows potential for treating both HER2-positive and trastuzumab-resistant breast cancers.
- The findings support the development of early-phase clinical trials (Phase I-II).